Clinical Trial

Radiotherapy for Refractory Hidradenitis Suppurativa

Study acronym: RADIANTSUPPoRT
Recruiting
View on ClinicalTrials.gov →
Summary
The goal of this clinical trial is to learn if high-dose radiotherapy can provide sustained disease relief in moderate to severe, treatment resistant Hidradenitis suppurativa patients; could include any of the following: any sex/gender, and those greater then 18 years old. The main question\[s\] it aims to answer are: Outcome measure 1: Will radiotherapy change the number of inflammatory nodules, abscesses, and draining sinus tracts in the treated axilla compared with the untreated axilla? Outcome measure 2: Will radiotherapy positively change a patient's quality of life, pain levels and symptom burden? Participants will receive radiotherapy to one axilla affected by hidradenitis suppurativa. The contralateral axilla will not receive radiotherapy and will continue receiving the standard treatment regimen. Participants will... * Attend a baseline dermatology skin evaluation, complete multiple surveys and an optional participation in a biopsy * Attend multiple radiation sessions over 5 weeks * Attend 2 follow up visits with dermatology for skin evaluation, complete follow up surveys, and an optional biopsy.
Protocol Amendment History 2 changes
critical Recruitment opened 2026-05-16
notable Primary completion pushed: 2027-03-01 -> 2027-05-01 2026-05-16
Trial Details
NCT Number NCT07414550
Lead Sponsor Thomas Jefferson University
Conditions Hidradenitis Suppurativa (HS)
Enrollment 10 participants
Start Date 2026-05-01
Primary Completion 2027-05-01 (estimated)
Study Completion 2028-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-05-15